#United States #FDA Approval #Mumbai #Lupin Limited #Ranluspec

Lupin Receives FDA Approval for Ranluspec™ Injection

Global pharmaceutical leader Lupin Limited made headlines with the recent announcement of their Ranluspec™ (ranibizumab) injection receiving approval from the United States Food and Drug Administration (U.S. FDA). This marks a notable accomplishment for the company as it solidifies their standing in the biopharmaceutical sector by introducing an interchangeable biosimilar referencing Genentech’s Lucentis®.

A Significant Step Forward

The approval of Ranluspec™ is particularly significant as it designates the product as the only interchangeable biosimilar of ranibizumab available in the U.S. Both the vial and pre-filled syringe (PFS) presentations are approved for the two strengths already available in Lucentis®: 0.3 mg (0.05 mL of 6 mg/mL) and 0.5 mg (0.05 mL of 10 mg/mL). This achievement further enhances Lupin's portfolio of biosimilars, emphasizing their commitment to providing innovative healthcare solutions.

Targeted Treatment for Serious Eye Conditions

Ranibizumab, the active component of Ranluspec™, is a recombinant humanized IgG1 monoclonal antibody fragment designed to inhibit vascular endothelial growth factor A. This therapeutic agent is crucial in treating various serious eye conditions, including:

• - Neovascular (wet) age-related macular degeneration
• - Macular edema following retinal vein occlusion
• - Diabetic macular edema
• - Diabetic retinopathy
• - Myopic choroidal neovascularization

Given the prevalence of these conditions, the introduction of Ranluspec™ is expected to improve patient access to effective treatments, enhancing health outcomes in communities across the United States.

Leadership Thoughts

Vinita Gupta, CEO of Lupin, expressed her enthusiasm about this approval, stating, “As our second U.S. biosimilar, Ranibizumab adds depth to our biosimilars portfolio, reflecting our progress in complex biologics while expanding patient access to proven vision therapies.” Meanwhile, Nilesh Gupta, Managing Director of Lupin, noted the approval as a testament to their scientifically rigorous approach and advanced manufacturing capabilities, indicating a strong commitment to expanding their biosimilar portfolio.

Further emphasizing the company’s dedication, Dr. Cyrus Karkaria, President of Biotechnology at Lupin, asserted that the U.S. FDA's approval of their biosimilar ranibizumab not only highlights their expertise in biologics development but also their commitment to providing advanced, affordable therapies to patients worldwide.

Company Overview

Founded in Mumbai, India, Lupin Limited has established itself as a global leader in pharmaceuticals, with a presence in over 100 markets. The company specializes in various pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Its diverse offerings are crucial to addressing global health needs and establishing a strong foothold in multiple therapy areas, such as respiratory, cardiovascular, and women’s health, amongst others.

Lupin’s global reach is supported by its 15 advanced manufacturing sites and 7 dedicated research centers, employing over 24,000 professionals worldwide. The company is not only committed to producing high-quality medicines but also focused on improving patient health outcomes through its subsidiaries, including Lupin Diagnostics and Lupin Digital Health.

Future Outlook

The FDA’s approval of Ranluspec™ is just one of several innovative steps Lupin is taking to enhance their therapeutic offerings and patient accessibility. As they continue to expand their biosimilars portfolio, Lupin strives to bring high-quality, affordable healthcare solutions to various patient populations, helping to improve the overall landscape of health care.

For more on Lupin and its innovative healthcare offerings, visit www.lupin.com or connect with them on LinkedIn.